Prostate Cancer News A curated look at the most recent external media coverage on prostate cancer: research breakthroughs, data insights, well-known patients, trending discussions, news coverage, and thought-provoking editorials. See Also: Stay Informed Page Jump To Jump To Latest News Full 2024 Archive 2023 Highlights Recent Headlines AstraZeneca, Zero Prostate Cancer rev up early detection push at Memorial Day weekend NASCAR races AstraZeneca and ZERO Prostate Cancer are teaming up during Memorial Day weekend NASCAR events to promote early prostate cancer detection—spotlighting veterans' risk and encouraging screenings. The pros and cons of PSA tests for prostate cancer for midlife and older men President Biden’s Prostate Cancer: Black Men Pay Attention Biden’s cancer raises questions around screening, timing Why Biden may not have known about his 'aggressive' prostate cancer until recently Want even more news?In addition to the external news stories, check out ZERO's in-depth resources:Newsletters: general news & community updates, as well as our special-topic email newsletters on medical research, advanced prostate cancer, and government relations/advocacy.Blog: Our Journey to ZERO blog has commentary and discussion about what's happening in the prostate cancer community, stories and inspiration from people impacted by the disease, and insights on news and current events.Podcasts: interesting conversations from experts, celebrities, and thought leaders in the prostate cancer world, on topics ranging from sexual intimacy, to health equity, and celebrity patients sharing their stories.Community News: ZERO In the News has public-media coverage of stories from patients, caregivers, and ZERO Champions, as well as local events, advocacy efforts, and updates about what's happening at ZERO.Press & Media Resources: reporters, editors, and researchers working on prostate cancer can find official press releases, contact information, video footage, and more. 2024 Archives All 2024 Articles The Lancet: Prostate Cancer Cases Expected to Double Worldwide between 2020 and 2040, New Analysis Suggests The Lancet Commission on prostate cancer projects that annual global cases will double from 1.4 million in 2020 to 2.9 million by 2040, with deaths rising 85% to nearly 700,000, mainly in low- and middle-income countries, and calls for improved early detection programs, increased awareness, expanded treatment capacity, and more research on ethnic disparities. Cabozantinib Plus Atezolizumab Improves Progression-Free Survival The combination of cabozantinib and atezolizumab significantly improved progression-free survival compared to second-line hormone therapy in patients with metastatic castration-resistant prostate cancer that progressed after initial hormone therapy in the CONTACT-02 trial. American Cancer Society Reports 2024 Facts & Figures The American Cancer Society's Facts & Figures report provides vital insights for 2024, where the U.S. faces a surge in cancer cases, urging attention to early detection, especially in prostate cancer. Disparities persist, underscoring the need for equity. Prostate Cancer Diagnosis of Secretary Lloyd Austin Draws Attention to Disease 2023 Highlights Full 2023 Archive Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy* in nonmetastatic castration-sensitive prostate cancer. Educating Patients and Caregivers About Prostate Cancer Dr. Alicia Morgans emphasizes the importance of educating prostate cancer patients and caregivers through trusted resources, like the Prostate Cancer Foundation and ZERO Prostate Cancer, and encourages open communication with medical teams, addressing topics such as cancer curability, treatment options, sexual health, mental health, and the need for support in the context of prostate cancer care. Listen: New Bill Aims to Reduce Prostate Cancer Deaths in D.C. A new bill in D.C. aims to reduce high prostate cancer fatality rates, especially among black men, by mandating annual insurance coverage for prostate cancer screenings, addressing disparities in access to testing and improving early diagnosis for better survival rates. When Screening for Prostate Cancer Comes Too Late Prostate cancer screening methods are under review for better targeting high-risk groups and addressing stagnant death rates and late-stage diagnoses. U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval Some Men with Prostate Cancer Can Avoid, Delay Harsh Treatments, Study Finds More men with prostate cancer could afford to delay their treatment, a decades-long study has found, suggesting that active monitoring by health-care professionals is an equally valid — and less harsh — option. PRESTO Trial Aims to Help Guide Treatment for Patients with Rising PSA After Surgery Clinical Trials of New Therapies for Advanced Prostate Cancer Full Archives See All Past News Articles Prostate Cancer News Archive More Ways to Stay Informed Check out our official news and statements, blog stories, and see who's talking about us! ZERO in the News ZERO in the News Read features about ZERO Prostate Cancer in the news—covering events, personal stories, advocacy efforts, and more! Blogs Blogs Our blogs feature commentary and discussion about what's happening in the prostate cancer community, stories and inspiration from people impacted by the disease, and insights on news and current events. Press & Media Inquiries Press & Media Inquiries Explore our newsroom for press releases and official statements about ZERO's latest updates, achievements, and partnerships.
Recent Headlines AstraZeneca, Zero Prostate Cancer rev up early detection push at Memorial Day weekend NASCAR races AstraZeneca and ZERO Prostate Cancer are teaming up during Memorial Day weekend NASCAR events to promote early prostate cancer detection—spotlighting veterans' risk and encouraging screenings. The pros and cons of PSA tests for prostate cancer for midlife and older men President Biden’s Prostate Cancer: Black Men Pay Attention Biden’s cancer raises questions around screening, timing Why Biden may not have known about his 'aggressive' prostate cancer until recently
Want even more news?In addition to the external news stories, check out ZERO's in-depth resources:Newsletters: general news & community updates, as well as our special-topic email newsletters on medical research, advanced prostate cancer, and government relations/advocacy.Blog: Our Journey to ZERO blog has commentary and discussion about what's happening in the prostate cancer community, stories and inspiration from people impacted by the disease, and insights on news and current events.Podcasts: interesting conversations from experts, celebrities, and thought leaders in the prostate cancer world, on topics ranging from sexual intimacy, to health equity, and celebrity patients sharing their stories.Community News: ZERO In the News has public-media coverage of stories from patients, caregivers, and ZERO Champions, as well as local events, advocacy efforts, and updates about what's happening at ZERO.Press & Media Resources: reporters, editors, and researchers working on prostate cancer can find official press releases, contact information, video footage, and more.
2024 Archives All 2024 Articles The Lancet: Prostate Cancer Cases Expected to Double Worldwide between 2020 and 2040, New Analysis Suggests The Lancet Commission on prostate cancer projects that annual global cases will double from 1.4 million in 2020 to 2.9 million by 2040, with deaths rising 85% to nearly 700,000, mainly in low- and middle-income countries, and calls for improved early detection programs, increased awareness, expanded treatment capacity, and more research on ethnic disparities. Cabozantinib Plus Atezolizumab Improves Progression-Free Survival The combination of cabozantinib and atezolizumab significantly improved progression-free survival compared to second-line hormone therapy in patients with metastatic castration-resistant prostate cancer that progressed after initial hormone therapy in the CONTACT-02 trial. American Cancer Society Reports 2024 Facts & Figures The American Cancer Society's Facts & Figures report provides vital insights for 2024, where the U.S. faces a surge in cancer cases, urging attention to early detection, especially in prostate cancer. Disparities persist, underscoring the need for equity. Prostate Cancer Diagnosis of Secretary Lloyd Austin Draws Attention to Disease
2023 Highlights Full 2023 Archive Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy* in nonmetastatic castration-sensitive prostate cancer. Educating Patients and Caregivers About Prostate Cancer Dr. Alicia Morgans emphasizes the importance of educating prostate cancer patients and caregivers through trusted resources, like the Prostate Cancer Foundation and ZERO Prostate Cancer, and encourages open communication with medical teams, addressing topics such as cancer curability, treatment options, sexual health, mental health, and the need for support in the context of prostate cancer care. Listen: New Bill Aims to Reduce Prostate Cancer Deaths in D.C. A new bill in D.C. aims to reduce high prostate cancer fatality rates, especially among black men, by mandating annual insurance coverage for prostate cancer screenings, addressing disparities in access to testing and improving early diagnosis for better survival rates. When Screening for Prostate Cancer Comes Too Late Prostate cancer screening methods are under review for better targeting high-risk groups and addressing stagnant death rates and late-stage diagnoses. U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval Some Men with Prostate Cancer Can Avoid, Delay Harsh Treatments, Study Finds More men with prostate cancer could afford to delay their treatment, a decades-long study has found, suggesting that active monitoring by health-care professionals is an equally valid — and less harsh — option. PRESTO Trial Aims to Help Guide Treatment for Patients with Rising PSA After Surgery Clinical Trials of New Therapies for Advanced Prostate Cancer
More Ways to Stay Informed Check out our official news and statements, blog stories, and see who's talking about us! ZERO in the News ZERO in the News Read features about ZERO Prostate Cancer in the news—covering events, personal stories, advocacy efforts, and more! Blogs Blogs Our blogs feature commentary and discussion about what's happening in the prostate cancer community, stories and inspiration from people impacted by the disease, and insights on news and current events. Press & Media Inquiries Press & Media Inquiries Explore our newsroom for press releases and official statements about ZERO's latest updates, achievements, and partnerships.
